KMCSHIL137.80

K M C Speciality Hospitals (India) Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersDRAGARWQKOVAILOTUSEYEGPTHEALTHGKSLSHALBYINDRAMEDCOARTEMISMED
View
In ₹ Crore except Per Share
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
FY24
31/03/2024
Revenue from Operations136.1155.8177.2
Other Income2.13.1
Total Income138.2158.9180.7
Expenses
+ Cost of Materials Consumed2.72.93.6
+ Purchases of Stock-in-Trade17.920.420.7
+ Changes in Inventories-0.0-0.30.2
+ Employee Benefit Expense27.131.238.3
+ Finance Costs0.70.81.2
+ Depreciation & Amortisation6.57.69.2
+ Other Expenses51.260.3
Total Expenses122.9140.2
EBITDA37.241.347.4
EBIT30.633.738.2
Profit
Pretax Income32.136.040.6
+ Current Tax8.49.98.8
+ Deferred Tax-0.4-0.71.4
Tax Expense8.49.310.2
Net Income23.726.730.4
+ Other Comprehensive Income-0.3
Total Comprehensive Income23.526.730.1
Per Share
Basic EPS1.451.641.86
Diluted EPS1.86
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit115.5132.8152.8
Gross Margin %84.8985.2586.21
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY24 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.